Advertisement

Prediction research of neuroleptic treatment outcome in schizophrenia — state of the art: 1978–1993

  • A. G. Awad

Abstract

In spite of the proven benefits of neuroleptics in reducing acute psychotic symptoms and in preventing relapse in many schizophrenic patients, not all patients benefit equally from neuroleptic therapy. The marked variability of the course in schizophrenia and its response to drug therapy are widely recognized (Awad 1989). Not surprisingly then, a good deal of interst has been devoted to predictive research and prognostic issues in general. Bellak (1948), surveying almost three decades of extensive literature on schizophrenia research concluded;

‘...the criteria for improvement, recovey and all other factors pertaining to prognosis are vague and disorderly.’

Keywords

Schizophrenic Patient Neuroleptic Treatment Prediction Research Bioi Psychiatry Neuroleptic Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Asarnow RF, Marder Sr, Mintz J et al. (1988) Differential effects of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information processing abilities. Arch Gen Psychiatry 45:822–826.PubMedGoogle Scholar
  2. Awad AG, Hogan TP (1985a) Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 9:885–888.Google Scholar
  3. Awad AG, Hogan TP (1985b) Towards the development of strategy for individualized drug therapy in schizophrenia. The predictive value of early subjective response and symptom change. J Clin Pharmacol 6:461.Google Scholar
  4. Awad AG, Hogan TP (1988a) Drug therapy in schizophrenia — prediction of outcome. Schizophr Res 1:222.Google Scholar
  5. Awad AG, Hogan TP (1988b) Diagnostic criteria as a predictor of drug response in schizophrenia. Med Sci Res 16:199–200.Google Scholar
  6. Awad AG (1989) Drug therapy in schizophrenia — variability of outcome and prediction of response. Can J Psychiatry 34:711–720.PubMedGoogle Scholar
  7. Awad AG (1992) Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Comm Psychiatry 43:262–265.Google Scholar
  8. Awad AG (1993a) Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19:609–618.PubMedGoogle Scholar
  9. Awad AG (1993a) Methodological and design issues in clinical trials of new neuroleptics: an overview. Br J Psychiatry 163 [Suppl] 22:51–57.Google Scholar
  10. Awad AG, Hogan TP (1994) Subjecitve response to neuroleptics and quality of life: implications for treatment outcome. Acta Psychiatr Scand 89 [Suppl] 380:27–32.Google Scholar
  11. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79–91.PubMedGoogle Scholar
  12. Bartko G, Herezeg I, Bekesi M (1987) Predicting outcome of neuroleptic therapy on the basis of subjective response and early clinical improvement. J Clin Psychiatry 48:363–365.PubMedGoogle Scholar
  13. Bartko G, Frecska E, Horvath S et al. (1990) Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients. Acta Psychiatr Scand 82:408–412.PubMedGoogle Scholar
  14. Bellak L (1948) Dementia precox. Grune & Stratton, New York.Google Scholar
  15. Bigelow LB, Kirch DG, Braun T et al. (1985) Absence of relationship of serum haloperidol concentrate and clinical. Psychopharmacol Bull 21:66–68.PubMedGoogle Scholar
  16. Bleeker JAC, Dingemans PM, Frohn-De Wunder ML (1984) Plasma level and effect of low dose haloperidol in acute psychosis. Psychopharmacol Bull 20:317–319.PubMedGoogle Scholar
  17. Bowers MB, Swigar ME, Jatlow PI et al. (1984) Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 45:248–251.PubMedGoogle Scholar
  18. Bowers MB, Swigar ME, Jatlow PI et al. (1986) Early neuroleptic response in psychotic women and men: correlation with plasma HVA and MHPG. Compr Psychiatry 27:181–185.PubMedGoogle Scholar
  19. Bowers MB, Swigar ME, Jatlow PI et al. (1987) Early neuroleptic response in clinical profiles and catecholamine metabolites. J Clin Psychopharmacol 7:83–86.PubMedGoogle Scholar
  20. Bowers MB (1991) Characteristics of psychotic inpatients with high or low HVA levels at admission. Am J Psychiatry 148:240–243.PubMedGoogle Scholar
  21. Breier A, Wolkowitz OM, Doran AR et al. (1987) Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 144:1549–1555.PubMedGoogle Scholar
  22. Buchsbaum M, Potkin SG, Siegel BV et al. (1992) Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 49:966–974.PubMedGoogle Scholar
  23. Carpenter WT, Bartko JJ, Strauss JS et al. (1978) Signs and symptoms as predictors of outcome. A report from the International Pilot Study of Schizophrenia. Am J Psychiatry 135:940–945.PubMedGoogle Scholar
  24. Carpenter ET, Strauss JS (1991) The prediction of outcome in schizophrenia. IV. Eleven-year follow-up of the Washington IPSS Cohort. J Nerv Ment Dis 179:517–525.PubMedGoogle Scholar
  25. Chang WH, Chen TY, Lin SK et al. (1990) Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept. Biol Psychiatry 27:510–518.PubMedGoogle Scholar
  26. Cohen BM, Baldessarini RJ (1981) Haloperidol and clinical response. Am J Psychiatry 138:1513–1514.PubMedGoogle Scholar
  27. Coppens HJ, Sloff CJ, Paans AMJ et al. (1991) High central D2 dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry 29:629–634.PubMedGoogle Scholar
  28. Cowen PJ, Gadhiri B et al. (1985) Response of prolactin and growth hormone to L-tryptophan in fusion: effects in normal subjects and schizophrenic patients receiving neuroleptics. Psychopharmacology 86:164–169.PubMedGoogle Scholar
  29. Czabor P, Volavka J (1991) Pretreatment EEG predicts short-term response to haloperidol treatment. Biol Psychiatry 137:383–386.Google Scholar
  30. Davidson M, Kahn RS, Knott P et al. (1991) The effect of neuroleptic treatment on plasma homovanillic acid concentrations and schizophrenic symptoms. Arch Gen Psychiatry 48:910–913.PubMedGoogle Scholar
  31. Davies RK, Neil JF (1979) Cerebral dysrythmia in schizophrenics; clinical correlates. In: Bellak L (ed) Psychiatric aspects of minimal brain dysfunction in adults. Grune & Stratton New York, pp 139–150.Google Scholar
  32. Davilla R, Manero E, Zumarraga M et al. (1988) Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 45:564–567.Google Scholar
  33. Davis JM, Ericksen SE, Hurt S et al. (1985) Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol Bull 21: 48–51.PubMedGoogle Scholar
  34. DeLisi LE, Schwartz CC, Targum SD et al. (1983) Ventricular brain enlargement and outcome of acute schizophreniform disorder. Psychiatry Res 9:169–171.PubMedGoogle Scholar
  35. Deutch AY, Moghaddam B, Innis RB et al. (1991) Mechanism of action of atypical antipsychotic drugs, implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:129–156.Google Scholar
  36. Dixon PA, Oforah E, Makanjuala R (1982) Predicitve indices for chlorpromazine therapy in schizophrenia. Br J Clin Pharmacol 14:273–277.PubMedGoogle Scholar
  37. Donnely EF, Weinberger DR et al. (1980) Cognitve impairment associated with morphologic brain abnormalities on computerized axil tomography in chronic schizophrenic patients. J Nerv Ment Dis 168:35–39.Google Scholar
  38. Dysken MW, Javaid JI, Chang SS et al. (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology 73:205–210.PubMedGoogle Scholar
  39. Extein I, Augusthy KA, Gold MA et al. (1982) Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull 18:156–158.PubMedGoogle Scholar
  40. Ferrier IN, Johnston EC, Crow TJ (1984) Hormonal effects of apomorphine in schizophrenia. Br J Psychiatry 144:349–357.PubMedGoogle Scholar
  41. Frith CD, Stevens M, Johnstone EC et al. (1979) Skin conductance responsivity during acute episodes of schizophrenia as a predictor of symptomatic improvement. Psychol Med 9:101–106.PubMedGoogle Scholar
  42. Gaebel W, Pietzcker A, Ulrich G et al. (1988) Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with Perazine. Pharmacopsychiatry 21:384–386.PubMedGoogle Scholar
  43. Gattaz WF, Rost W, Kohlmyer K et al. (1988) CT Scans and neuroleptic response in schizophrenia: a multidimensional approach. Psychiatry Res 26:293–303.PubMedGoogle Scholar
  44. Gift TE, Strauss JS, Kokes RF (1980) Schizophrenia, affect and outcome. Am J Psychiatry 137:580–585.PubMedGoogle Scholar
  45. Golden CJ, Carpenter B, Wilkening B et al. (1983) The relationship of the Brief Psychiatric Rating Scale to neuropsychological deficits in phenothiazine treated schizophrenics. Psy-chopharmacol Bull 19:513–517.Google Scholar
  46. Harvey PD, Davidson M, Powchik P et al. (1991) The course and clinical predictors of treatment response in schizophrenia. Schizophr Res 5:161–166.PubMedGoogle Scholar
  47. Heizer JE, Brockington IF, Kendall RE (1981) Predictive validity of DSM-III and Feigner definitions of schizophrenia. Arch Gen Psychiatry 38:791–797.Google Scholar
  48. Hogan TP, Awad AG (1992) Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 22:347–352.PubMedGoogle Scholar
  49. Itil TM, Shapiro D, Schneider SJ et al. (1981) Computerized EEG as a predictor of drug response in treatment resistant schizophrenia. J Nerv Ment Dis 169:629–637.PubMedGoogle Scholar
  50. Javaid JI, Sharma R, Janicak P et al. (1990) Plasma HVA in psychotic patients: longitudinal studies. Psychopharmacol Bull 26:361–365.PubMedGoogle Scholar
  51. Kane J, Hornigfeld G, Singer J et al. (1989) Clozapine for the treatment-resistant schizophrenic — a double blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796.Google Scholar
  52. Kaplan MJ, Lazoff M, Lukin R et al. (1990) Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics. Biol Psychiatry 27:205–214.PubMedGoogle Scholar
  53. Kemali D, Maj M (1985) Clinical and neuropsychological correlates of cerebral ventricular enlargement in schizophrenia. J Psychiatr Res 4:587–596.Google Scholar
  54. Kolakowska T, Williams AO, Ardren M, Reverley MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome. 1. Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 146:229–239.PubMedGoogle Scholar
  55. Kulhara P, Chandiramani K (1988) Outcome of schizophrenia in India using various diagnostic systems. Schizophr Res 1:339–349.PubMedGoogle Scholar
  56. Lieberman JA, Jody D, Geislar S et al. (1993) Time course and biologic correlates of treatment response in first episode schizophrenia. Arch Gen Psychiatry 50:369–376.PubMedGoogle Scholar
  57. Lindstrom EM, Ohlund LS, Lindstrom LH et al. (1992) Symptomatology and electrodernal activity as predictor of neuroleptic response in young male schizophrenic inpatients. Psychiatr Res 42:145–148.Google Scholar
  58. Luchins DJ, Lewine RJR, Meltzer HY (1983) Lateral ventricular size in the psychosis in relation to psychopathology and therapeutic and adverse response to medications. Psychopharmacol Bull 19:518–523.PubMedGoogle Scholar
  59. Lydiard BR, Laird LK (1988) Prediction of response to antipsychotics. J Clin Psychopharmacol 8:3–13.PubMedGoogle Scholar
  60. Maglozzi JR, Jollister LE, Arnold KV et al. (1981) Relationship of serum haloperidol level to clinical response in schizophrenic patients. Am J Psychiatry 138:365–367.Google Scholar
  61. Manschreck TC, Ames D (1984) Neurologic features and psychopathology in schizophrenic disorders. Biol Psychiatry 19:703–719.PubMedGoogle Scholar
  62. Marder SR, Asarmow RF, Van Putten T (1984) Information processing and neuroleptic response in acute schizophrenic patients. Psychiatry Res 13:41–49.PubMedGoogle Scholar
  63. May PRA, Goldberg SC (1978) Prediction of schizophrenic patients’ response to pharmacotherapy. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1135–1139.Google Scholar
  64. May PRA, Itil TM, Van Putten T (1982) Preliminary attempt to relate individual differences in EEG, test dose response to clinical effect. Biol Psychiatry 17:599–603.PubMedGoogle Scholar
  65. May PRA, Van Putten T, Jenden D et al. (1981) Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Arch Gen Psychiatry 38:202–207.PubMedGoogle Scholar
  66. May PRA, Van Putten T, Yale C (1980) Predicting outcome of antipsychotic drug treatment from early response. Am J Psychiatry 37:1088–1090.Google Scholar
  67. Mazure CM, Nelson CJ, Jatlow PI (1991) Plasma free homovanillic acid as a predictor of clinical response in acute psychosis. Biol Psychiatry 3:475–482.Google Scholar
  68. Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6:329–338.PubMedGoogle Scholar
  69. Möller HJ, Scharl W, von Zerssen D (1985) Can the result of neuroleptic treatment be predicted? An empirical investigation of schizophrenic patients. Pharmacopsychiatry 18:52–53.Google Scholar
  70. Neborsky R, Janowsky D, Munson E et al. (1982) Behavioral prediction of response to haloperidol in a test dose strategy. J Clin Psychiatry 43:157–158.PubMedGoogle Scholar
  71. Nedopil N, Ruther E (1981) Initial improvement as a predictor of outcome of neuroleptic treatment. Pharmacopsychiatrica 14:205–214.Google Scholar
  72. Nedopil N, Pflieger R, Ruther E (1983) The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Pharmacopsychiatry 16:201–205.Google Scholar
  73. Pickar D, Labarca R, Linnoila M et al. (1984) Neuroleptic induced decrease in plasma homo-vanillic acid and antipsychotic activity in schizophrenic patients. Science 225:954–957.PubMedGoogle Scholar
  74. Pickar D, Labarca R, Doran AR et al. (1986) Longitudinal measurements of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 43:669–676.PubMedGoogle Scholar
  75. Rifkin A, Seshagiri D, Karajgi B et al. (1988) Neuroleptic treatment and prediction of response. Psychopharmacol Bull 24:169–171.PubMedGoogle Scholar
  76. Ritzier B (1981) Paranoia — prognosis and treatment. A review. Schizophr Bull 7:710–728.Google Scholar
  77. Rotrosen J, Angrist O, Gershon S et al. (1979) Neuroendocrine effects of apomorphine, characteristics of response patterns and applications to schizophrenia research. Br J Psychiatry 135:444–456.PubMedGoogle Scholar
  78. Schneider SJ (1982) Electrodernal activity and therapeutic response to neuroleptic treatment in chronic schizophrenic in-patients. Psycho Med 12:607–613.Google Scholar
  79. Schulz SC, Sinicrope P, Kishore P et al. (1983) Treatment response and ventricular brain enlargement in young schizophrenic patients. Psychopharmacol Bull 19:510–512.PubMedGoogle Scholar
  80. Seeman MV (1983) Interaction of sex, age and neuroleptic dose. Compr Psychiatry 24:125–128.PubMedGoogle Scholar
  81. Sharma R, Javaid JI, Janicak P et al. (1989) Plasma and CSF HVA before and after pharmacological treatment. Psychiatry Res 28:79–104.Google Scholar
  82. Smith RC, Largen J, Calderon M et al. (1983) Morphological and neuropsychological abnormalities as predictor of clinical response of psychotropic drugs. Psychopharmacol Bull 19:505–509.PubMedGoogle Scholar
  83. Smith RC, Largen J, Vroulis G et al. (1992) Neuropsychological test scores and clinical response to neuroleptic drugs in schizophrenic patients. Compr Psychiatry 33:139–145.PubMedGoogle Scholar
  84. Stern RG, Kahn RS, Davidson M (1993) Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am 16,2:313–338.PubMedGoogle Scholar
  85. Straube ER, Schiad HW, Rein W et al. (1987) Autonomic nervous system differences as predictors of short-term outcome in schizophrenia. Pharmacopsychiatry 20:105–110.PubMedGoogle Scholar
  86. Straube ER, Wagner W, Foerster K et al. (1989) Findings significant with respective to short and medium-term outcome in schizophrenia — preliminary report. Prog Neuropsycho-pharmacol Biol Psychiatry 13:185–197.Google Scholar
  87. Ulrich G, Gaebel W, Pietzker A et al. (1988) Prediction of neuroleptic on drug response in schizophrenic in-patients by EEG. Eur Arch Psychiatr Neurol Sci 237:144–155.Google Scholar
  88. Van Putten T, May PRA (1978) Subjective response as predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 35:477–480.PubMedGoogle Scholar
  89. Van Putten T, May PRA, Jenden DJ et al. (1980a) Plasma and saliva levels of chlorpromazine and subjective response. Am J Psychiatry 137:1241–1242.PubMedGoogle Scholar
  90. Van Putten T, May PRA, Marder SR (1980b) Subjective responses to thiothixene and chlorpromazine. Psychopharmacol Bull 16:36–38.PubMedGoogle Scholar
  91. Van Putten T, May PRA, Marder SR et al. (1981) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38:189–190.Google Scholar
  92. Van Putten T, Marder SR, May PRA et al. (1985) Is a plasma level of haloperidol clinically useful? Psychopharmacol Bull 21:61–64.Google Scholar
  93. Van Putten T, Marder SR (1986) Low-dose treatment strategies. J Clin Psychiatry [Suppl] 47:12–16.Google Scholar
  94. Van Putten T, Marder S, Aravagiri M et al. (1989) Plasma homovanillic acid as a predictor of response to fluphenazine treatment. Psychopharmacol Bull 1:89–91.Google Scholar
  95. Van Putten T, Aravagiri M, Marder SR et al. (1991) Plasma fluphenazine level and clinical response in newly admitted schizophrenic patients. Psychopharmacol Bull 27:91–96.PubMedGoogle Scholar
  96. Volavka J, Cooper TB (1987) Review of haloperidol blood level and clinical response: looking through the window. J Clin Psychopharmacol 7:25–30.PubMedGoogle Scholar
  97. Volavka J, Cooper TB, Meisner M et al. (1990) Haloperidol blood levels and effects in schizophrenia and schizo-affective disorder: a progress report. Psychopharmacol Bull 26:13–17.PubMedGoogle Scholar
  98. Weinberger DR, Torrey EF, Neophytides AN (1979) Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 36:735–739.PubMedGoogle Scholar
  99. Weinberger DR, Bigelow LB, Kleinman JE et al. (1980) Cerebral ventricular enlargement in chronic schizophrenia: an association with poor response to treatment. Arch Gen Psychiatry 37:11–13.PubMedGoogle Scholar
  100. Williams AO, Reveley MA, Kolakowska T et al. (1985) Schizophrenia with good and poor outcome. II. Cerebral ventricular size and its clinical significance. Br J Psychiatry 146:239–246.PubMedGoogle Scholar
  101. Young MA, Meltzer HY (1980) The relationship of demographic, clinical and outcome variables to neuroleptic treatment requirements. Schizophr Bull 6:88–101.PubMedGoogle Scholar
  102. Zahn TP, Carpenter WT, McGlashan TH (1981) Autonomic nervous system activity in acute schizophrenia. II. Relationship to short-term prognosis and clinical state. Arch Gen Psychiatry 38:260–266.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • A. G. Awad
    • 1
  1. 1.Department of PsychiatryThe Wellesley HospitalTorontoCanada

Personalised recommendations